“We're seeing a medication class with the potential to reshape how providers generate revenue, where investors allocate capital, and how consumers engage with their health.”

John Teasley · said date not stated · reported 2026-08-20

John Teasley outlined how GLP-1 medications could alter healthcare revenue, capital allocation, and consumer health engagement.